Shin Nippon Biomedical Laboratories, Ltd.

DB:YB3 Stock Report

Market Cap: €428.9m

Shin Nippon Biomedical Laboratories Management

Management criteria checks 2/4

Shin Nippon Biomedical Laboratories' CEO is Ryoichi Nagata, appointed in Jan 1991, has a tenure of 33.92 years. directly owns 2.46% of the company’s shares, worth €10.55M. The average tenure of the management team and the board of directors is 2.5 years and 9.5 years respectively.

Key information

Ryoichi Nagata

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure33.9yrs
CEO ownership2.5%
Management average tenure2.5yrs
Board average tenure9.5yrs

Recent management updates

Recent updates

CEO

Ryoichi Nagata (66 yo)

33.9yrs

Tenure

JP¥144,061,000

Compensation

Dr. Ryoichi Nagata, M.D., Ph D., F.F.P.M., serves as President & Director of Satsuma Pharmaceuticals, Inc. since June 8, 2023 Also serves as it's Chief Executive Officer and Group Financial Officer since 2...

Leadership Team

NamePositionTenureCompensationOwnership
Ryoichi Nagata
President33.9yrsJP¥144.06m2.46%
€ 10.5m
Fumihiko Makino
Senior Executive Officer2.9yrsno datano data
Toshiyuki Iwata
Managing Executive Officerno datano datano data
Shinji Nitanda
Senior MD of Corporate Development & Corporate Tax Administration and Director2.5yrsno datano data
Kyomi Nagatoshi
Senior Managing Executive Officerno datano datano data
Ken Takanashi
Executive VP of Group Corporate Management & Global Business & Director20.5yrsno data0.090%
€ 385.2k
Satoshi Matsumoto
Managing Executive Officer & GM of Fisheries Divisionless than a yearno datano data
Hideshi Tsusaki
Senior MD1.9yrsno datano data
Terumasa Hirai
Managing Executive Officer & President and Representative Director of SNBL Ina Research Centerno datano datano data
Shu-Ichi Kanazashi
Managing Executive Officerless than a yearno datano data
Eishi Tsunozaki
Senior MD & Directorno datano data0.043%
€ 186.5k
Ichiro Nagata
Executive VPno datano data40.32%
€ 172.9m

2.5yrs

Average Tenure

57yo

Average Age

Experienced Management: YB3's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ryoichi Nagata
President41.7yrsJP¥144.06m2.46%
€ 10.5m
Shinji Nitanda
Senior MD of Corporate Development & Corporate Tax Administration and Director14.5yrsno datano data
Kyomi Nagatoshi
Senior Managing Executive Officerno datano datano data
Ken Takanashi
Executive VP of Group Corporate Management & Global Business & Director22yrsno data0.090%
€ 385.2k
Hideshi Tsusaki
Senior MD10.5yrsno datano data
Eishi Tsunozaki
Senior MD & Director10.5yrsno data0.043%
€ 186.5k
Ichiro Nagata
Executive VP4.5yrsno data40.32%
€ 172.9m
Shinichi Fukumoto
Independent Outside Director9.5yrsno data0.00096%
€ 4.1k
Takashi Yamashita
Independent Outside Director9.5yrsno data0.00096%
€ 4.1k
Tsuyoshi Hanada
Independent Outside Director4.5yrsno data0.0098%
€ 42.2k
Keiko Totani
Independent Outside Director3.5yrsno data0.0019%
€ 8.2k
Chizuru Horishita
Independent Outside Directorless than a yearno datano data

9.5yrs

Average Tenure

60yo

Average Age

Experienced Board: YB3's board of directors are considered experienced (9.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 21:50
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shin Nippon Biomedical Laboratories, Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuki TsukamotoBofA Global Research
Akitada IwasaDaiwa Securities Co. Ltd.
Masao YoshidaIchiyoshi Research Institute Inc.